BridgeBio Pharma, Inc.

MUN:2CL Stock Report

Market Cap: €5.2b

BridgeBio Pharma Management

Management criteria checks 2/4

BridgeBio Pharma's CEO is Neil Kumar, appointed in Apr 2015, has a tenure of 9.67 years. total yearly compensation is $12.16M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 3.65% of the company’s shares, worth €189.30M. The average tenure of the management team and the board of directors is 5.5 years and 4.9 years respectively.

Key information

Neil Kumar

Chief executive officer

US$12.2m

Total compensation

CEO salary percentage6.1%
CEO tenure9.7yrs
CEO ownership3.7%
Management average tenure5.5yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Neil Kumar's remuneration changed compared to BridgeBio Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$439m

Jun 30 2024n/an/a

-US$454m

Mar 31 2024n/an/a

-US$538m

Dec 31 2023US$12mUS$742k

-US$643m

Sep 30 2023n/an/a

-US$613m

Jun 30 2023n/an/a

-US$573m

Mar 31 2023n/an/a

-US$425m

Dec 31 2022US$7mUS$1m

-US$481m

Sep 30 2022n/an/a

-US$491m

Jun 30 2022n/an/a

-US$509m

Mar 31 2022n/an/a

-US$596m

Dec 31 2021US$26mUS$725k

-US$563m

Sep 30 2021n/an/a

-US$535m

Jun 30 2021n/an/a

-US$495m

Mar 31 2021n/an/a

-US$520m

Dec 31 2020US$10mUS$550k

-US$449m

Sep 30 2020n/an/a

-US$402m

Jun 30 2020n/an/a

-US$346m

Mar 31 2020n/an/a

-US$291m

Dec 31 2019US$26mUS$503k

-US$261m

Sep 30 2019n/an/a

-US$226m

Jun 30 2019n/an/a

-US$197m

Mar 31 2019n/an/a

-US$155m

Dec 31 2018US$450kUS$450k

-US$131m

Compensation vs Market: Neil's total compensation ($USD12.16M) is above average for companies of similar size in the German market ($USD3.33M).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.

CEO

Neil Kumar (45 yo)

9.7yrs

Tenure

US$12,158,626

Compensation

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

Leadership Team

NamePositionTenureCompensationOwnership
Neil Kumar
Co-Founder9.7yrsUS$12.16m3.65%
€ 189.3m
Charles Homcy
Co-Founderno dataUS$1.11m0.65%
€ 33.7m
Frank McCormick
Co-Founderno dataUS$1.74m0.58%
€ 30.2m
Brian Stephenson
CFO & Secretary6.2yrsUS$6.65m0.050%
€ 2.6m
Richard Scheller
Chairman of Research & Development5.9yrsUS$2.01mno data
Thomas Trimarchi
President & COOless than a yearno data0.23%
€ 11.7m
Uma Sinha
Chief Scientific Officer8.7yrsUS$2.75mno data
Grace Rauh
Vice President of Communicationsno datano datano data
Eli Wallace
Chief Scientific Officer of Oncology5yrsno datano data
Eric David
Chief Executive Officer of Gene Therapyno datano datano data
Matthew Outten
Chief Commercial Officer3.6yrsno datano data
Adora Ndu
Chief Regulatory Affairs Officer2.9yrsno datano data

5.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 2CL's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Neil Kumar
Co-Founder9.7yrsUS$12.16m3.65%
€ 189.3m
Charles Homcy
Co-Founder6.1yrsUS$1.11m0.65%
€ 33.7m
Frank McCormick
Co-Founder1.2yrsUS$1.74m0.58%
€ 30.2m
Fred Hassan
Independent Director3.3yrsUS$600.00k0.010%
€ 528.9k
Ronald Daniels
Independent Director4.8yrsUS$600.00k0.0055%
€ 284.9k
Eric Aguiar
Independent Director5.8yrsUS$600.00k0%
€ 0
Randal Scott
Independent Director4.5yrsUS$600.00k0.0048%
€ 246.6k
Ali Satvat
Independent Director8.8yrsUS$600.00k0%
€ 0
James Momtazee
Director8.8yrsUS$600.00k0.047%
€ 2.4m
Jennifer Cook
Director5yrsUS$600.00k0.0038%
€ 195.8k
Wen-Chaun Lo
Independent Director4.5yrsUS$600.00k0.13%
€ 7.0m
Andrea Ellis
Independent Director3.3yrsUS$600.00k0.0063%
€ 329.0k

4.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 2CL's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:55
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BridgeBio Pharma, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research